Metraipolis › archive › dc_e75dd8df307a

DOTAP-Based Hybrid Nanostructured Lipid Carriers for CRISPR-Cas9 RNP Delivery Targeting TGFB1 in Diabetic Nephropathy — Europe PMC PMID:41599201

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/41599201
DOI
10.3390/pharmaceutics18010094
License (as archived)
solo-consultazione
Archived
2026-11-06T22:10:14.210Z
SHA-256 of the archived text
42457c3dc214ff4264811fd36feccfc0b79f936854e41848e8613e39e5582125
Stable URL of this page
https://metraipolis.com/documento/dc_e75dd8df307a

How to cite

DOTAP-Based Hybrid Nanostructured Lipid Carriers for CRISPR-Cas9 RNP Delivery Targeting TGFB1 in Diabetic Nephropathy — Europe PMC PMID:41599201 — Europe PMC (en), https://europepmc.org/article/MED/41599201 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_e75dd8df307a (Metraipolis archive dc_e75dd8df307a, sha256 42457c3dc214ff4264811fd36feccfc0b79f936854e41848e8613e39e5582125)
BibTeX
@misc{dce75dd8df307a,
  title = {DOTAP-Based Hybrid Nanostructured Lipid Carriers for CRISPR-Cas9 RNP Delivery Targeting TGFB1 in Diabetic Nephropathy — Europe PMC PMID:41599201},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/41599201},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_e75dd8df307a; sha256 42457c3dc214ff4264811fd36feccfc0b79f936854e41848e8613e39e5582125},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41599201. Agents can read the archived copy with the MCP tool read_document.